Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10652322			
Filing Date		2003-08-29			
First Named Inventor Ashel		in et al.			
Art Unit		3635			
Examiner Name	Miche	le Yvonne Horton			
Attorney Docket Number		92/F00-003D			

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Patentee or Applicant of cited Document		Relev	s,Columns ant Passa as Appear	ges or		
	1	5524406		1996-06	i-11	Ragland						
	2	5709458		1998-01	1-20	Metz						
	3	6014844		2000-01	I-18	Thill						
If you wis	h to a	dd additional U.S. Pater							Add			
			HSP	ATEMIT		CATION PUBL	PROTECTIONS		Remove	>l		
	_		0.0	AILNI.	AFFER	- CATION FODI	LICATIONS			_		
Examiner Initial*	Cite No	Publication Number		Publica			entee or Applicant	Relev	s,Columns ant Passa as Appear	ges or		
		Publication Number	Kind	Publica		Name of Pate	entee or Applicant	Relev	ant Passa	ges or		
Initial*	No 1	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant iment	Relevi Figure	ant Passa is Appear	ges or		
Initial*	No 1		Kind Code ¹	Publica Date	ntion	Name of Pate of cited Docu	entee or Applicant iment	Relevi Figure	ant Passa is Appear	iges or		
Initial*	No 1		Kind Code ¹	Publica Date	ntion	Name of Pate of cited Docu	entee or Applicant iment	Relevi Figure	ant Passa is Appear	olumns elevant s or Re	Lines	

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Examiner Name

	Application Number		10652322		
	Filing Date		2003-08-29		
First Named Inventor Ashel		Ashel	in et al.		
	Art Unit		3635		
	Examiner Name	Miche	ele Yvonne Horton		
	Attorney Docket Number		92/F00-003D		

If you wish	to a	dd add	ditional Foreign Patent Document citation information please click the Add button	Add	
			NON-PATENT LITERATURE DOCUMENTS	Remove	
Examiner Initials*	Cite No	(bool	de name of the author (in CAPITAL LETTERS), title of the article (when appropri k, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-iss sher, city and/or country where published.		T5
	1				
If you wish	n to a	dd add	fitional non-patent literature document citation information please click the Add bu	utton Add	
			EXAMINER SIGNATURE		
Examiner	Signa	ture	Date Considered		
			reference considered, whether or not citation is in conformance with MPEP 609, rmance and not considered. Include copy of this form with next communication to		

1 See Kind Codes of USPTO Patent Documents at www.ISPTO.QQD/ or MPEP 90104. 2 Enter office that issued the document, by the hor-deter code (WIPO Standard ST3.) 2 for Junganese patent coursets, the included not the year of the insper or may preced the sental runber of the patent of being of the Emperor may preced the sental runber of the patent of being of the Emperor may preced the sental runber of the patent of being of the Emperor may preced the sental runber of the patent of being of the Emperor may preced the sental runber of the patent of the Emperor may not the Emperor of the Em

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10652322		
Filing Date		2003-08-29		
First Named Inventor Asheli		in et al.		
Art Unit		3635		
Examiner Name	Miche	ele Yvonne Horton		
Attorney Docket Numb	er	92/F00-003D		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the ap	propriate selection(s):
---------------	----------	-------------	-------------	-------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Keith R. Jarosık/	Date (YYYY-MM-DD)	2006-10-27
Name/Print	Kerth R. Jarosik	Registration Number	47 683

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandria, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 14450, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.